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Abstract: mRNA stability influences gene expression and translation in almost all living organisms,
and the levels of mRNA molecules in the cell are determined by a balance between production
and decay. Maintaining an accurate balance is crucial for the correct function of a wide variety of
biological processes and to maintain an appropriate cellular homeostasis. Long non-coding RNAs
(lncRNAs) have been shown to participate in the regulation of gene expression through different
molecular mechanisms, including mRNA stabilization. In this review we provide an overview on the
molecular mechanisms by which lncRNAs modulate mRNA stability and decay. We focus on how
lncRNAs interact with RNA binding proteins and microRNAs to avoid mRNA degradation, and also
on how lncRNAs modulate epitranscriptomic marks that directly impact on mRNA stability.
Keywords: long non-coding RNA; mRNA stability; RNA binding protein; microRNA;
gene expression
1. Introduction
Gene expression and translation is influenced by messenger RNA (mRNA) stability
in almost all living organisms. mRNA from bacterial cells can last from seconds to more
than one hour, but on average it stays functional between 1 and 3 min [1,2]. Conversely,
the lifetime of mammalian mRNA ranges from a couple of minutes to even days, making
eukaryotic mRNA more stable than bacterial mRNA. However, from bacteria to mammals,
mRNA lifetime needs to be finely regulated in order to enable correct cell homeostasis [1].
The control of the abundance of a particular mRNA fluctuates to adapt to environmental
changes, cell growth, differentiation, or to adjust to an unfamiliar situation [3,4]. In this
line, the regulation of mRNA stability is essential for tissues and organs exposed to stress
signals, such as starvation, infection, inflammation, toxins, or tissue invasion by immune
cells [5,6].
The levels of mRNA molecules in the cell are determined by a balance between
production and decay [7,8]. Maintaining an accurate balance is crucial for the correct
function of a wide variety of biological processes and for the maintenance of an appropriate
cellular homeostasis. Many variables such as primary and secondary structure, translation
rate and location, among others, influence mRNA stability [5,9,10], and thus minor changes
in the structure or the sequence of mRNA molecules might directly influence their half-life.
Eukaryotic mRNAs are transcribed in the nucleus, they are capped (7-methylguanosine
cap in 5′end), spliced, polyadenylated (poly(A) tail in 3′end), and lastly, mature mRNAs
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are exported to the cytoplasm where they are translated into the corresponding polypep-
tides [1]. Once in the cytoplasm, the 5′cap and the 3′tail serve to attract specific protein
complexes that regulate mRNA stability, via protecting mRNA molecules from the attack
of ribonucleases and decapping enzymes [1,9,11].
In the last few years, significant progress has been made towards the understand-
ing of mRNA degradation and stability. In general, the decay of mRNA molecules in
eukaryotic cells starts with the deadenylation and/or decapping of the mature mRNA,
followed by degradation carried out by exonucleases [12–15]. However, the regulation of
mRNA stability depends largely on how a three step process (deadenylation, decapping,
and degradation) is modulated by regulatory factors, and thus these factors should be taken
into account when analyzing the regulation of mRNA stability. Indeed, several studies
have pointed out the key role of RNA-binding proteins and miRNAs in the regulation
of this process [7,9,16,17]. In addition, long non-coding RNAs (lncRNAs) are emerging
as prominent regulators of mRNA stability and decay [3,4,18–21]. LncRNAs are RNA
molecules without protein coding potential with lengths exceeding 200 nucleotides [22].
They play important roles in biological processes such as chromatin remodeling, transcrip-
tional activation and interference, RNA processing, and mRNA translation [23]. Regarding
their mechanisms of action, different models have been proposed, including functioning
as signal, decoy, scaffold, guide, and enhancer RNAs [24]. Importantly, the expression of
lncRNAs occurs in a cell-, tissue-, and species-specific manner, and accumulating evidence
suggests that different splice variants of individual lncRNAs are also expressed in a cell-,
tissue-, and species-specific way [25].
In this review we provide an overview of the main molecular mechanisms by which
lncRNAs modulate mRNA stability and gene expression (Figure 1). A detailed descrip-
tion of how lncRNAs interact with target mRNAs, RNA binding proteins or miRNAs to
avoid mRNA degradation is provided and a brief explanation on how lncRNAs modulate
epitranscriptomic changes to impact on mRNA stability is also described.
Figure 1. Mechanisms of action of lncRNA-mediated mRNA stability regulation. LncRNAs can
modulate mRNA stability through different mechanisms: (A) Direct interaction with miRNA or RBP
binding sites in target mRNA; (B) Sequestration of miRNAs or RBPs to avoid their interaction with
mRNA molecules; (C) Acting as scaffolds to enhance RBP-mRNA interactions; (D) Interaction with
m6A machinery to modulate m6A levels of target mRNAs.
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2. LncRNAs Affecting mRNA Stability via miRNA Blockage
Recent several studies have been focused on the analysis of the cross-talk between
non-coding and coding RNAs to characterize the implication of these interactions in several
processes that include chromatin remodeling, mRNA and protein stability, transcription,
and mRNA turnover [26]. Accumulating evidence has demonstrated that microRNAs (miR-
NAs), which are non-coding RNA molecules of around 22 nucleotides, and long non-coding
RNAs, which are longer than 200 nucleotides, interact to regulate their own expression
and the expression of mRNAs through several molecular mechanisms [27–30]. MicroRNAs
can silence cytoplasmic mRNAs by triggering an endonuclease cleavage, by promoting
translation repression or by accelerating mRNA deadenylation and decapping [31,32].
Thus, miRNA blocking by lncRNAs can directly inhibit these processes, promoting mRNA
stabilization and inducing gene expression.
In this section, we will provide an overview of lncRNAs that prevent interaction of
miRNAs with target mRNAs to protect them from miRNA-driven degradation. These lncR-
NAs are referred to as competitive endogenous RNAs (ceRNAs), decoys or sponges [33].
LncRNAs can act as ceRNAs by two different mechanisms. On the one hand, they are able
to sequester miRNAs, avoiding their binding to target mRNAs, and on the other hand,
they can directly interact with target mRNA transcripts to block miRNA binding sites in
mRNA molecules. In this case, lncRNAs and miRNAs share common binding sites in the
target mRNA. The interactions between miRNAs and ceRNAs are crucial for the regulation
of several basal biological processes but have also been described to participate in different
pathogenic conditions.
Most lncRNAs that block miRNA activity to enhance mRNA stability are transcribed
from the opposite DNA strand to their paired (sometimes complementary) sense protein
coding genes and are known as natural antisense transcripts (NATs). Even though there are
some examples of NATs that code for proteins, such as Wrap53 [34] and DHPS [35], NATs
usually lack protein coding potential [36] and are generally classified as lncRNAs [37].
NATs can alter their paired sense gene expression by exerting their effect at different levels,
including transcription, mRNA processing, splicing, stability and translation [36,38–41].
Regarding the mechanisms by which NATs alter mRNA stability, the “Recycling hypothesis”
suggests that reversible RNA duplex formation might trigger conformational changes
in mRNA molecules, hindering the accessibility to RNA binding proteins (RBPs), both
stabilizing and destabilizing RBPs, and miRNAs [37].
The best characterized NAT is probably the lncRNA BACE1 antisense RNA (BACE1-
AS). This lncRNA is partially antisense to BACE1, a gene encoding the β-site amyloid
precursor protein cleaving enzyme 1, which plays a crucial role in the pathophysiology
of Alzheimer’s disease [42]. Interestingly, it has been shown that lncRNA BACE1-AS
is markedly up-regulated in brain samples from patients with Alzheimer’s disease and
promotes the stability of the BACE1 transcript [43]. The lncRNA BACE1-AS regulates the
expression of its sense partner through a synergistic mechanism that includes prevention
of miRNA-induced mRNA decay and translational repression. Specifically, miR-485-5p and
BACE1-AS share a common binding site in the sixth exon of BACE1 mRNA transcript, and
thus binding of BACE1-AS to this site avoids the interaction of miR-485-5p, hindering the
translational repression and destabilization of BACE1 mRNA by miR-485-5p, and eventually
elevating BACE1 levels [43].
Similar to BACE1-AS, PTB antisense RNA (PTB-AS) also modulates its sense mRNA
stability by masking miRNA binding sites [44]. PTB-AS binds to the 3′ untranslated region
(UTR) of PTBP1, a RBP that promotes gliomagenesis [45], and prevents miR-9 binding,
a neural-specific miRNA known to target the 3′ UTR of PTBP1 for degradation [46].
In addition, a lncRNA named FGFR3 antisense transcript 1 (FGFR3-AS1) which is
antisense to FGFR3 gene, was shown to be upregulated in an expression analysis performed
in tumorigenic tissue from patients with osteosarcoma, when compared to non-cancerous
tissue [30]. Bioinformatic analysis indicated that FGFR3-AS1 and FGFR3 formed a “tail-
to-tail” fully complementarity pairing pattern composed of 1053 nucleotides, suggesting
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a potential regulatory effect of FGFR3-AS1 in the expression of the FGFR3 gene. In silico
results were confirmed by RNA protection assays that showed that the non-overlapping
part of FGFR3 mRNA was totally digested, but the overlapping 3′UTR of FGFR3 mRNA was
protected from RNase digestion. Moreover, the authors showed that this antisense pairing
between FGFR3-AS1 and FGFR3 mRNA upregulated FGFR3 expression by increasing
FGFR3 mRNA stability. Interestingly, many miRNAs have been reported to bind to the
3′UTR of FGFR3, inducing FGFR3 mRNA degradation [47]. Thus, the antisense pairing
between FGFR3-AS1 and the 3′UTR of FGFR3 might block potential miRNA binding
sites, protecting FGFR3 from miRNA-induced degradation and/or translation inhibition.
However, whether FGFR3-AS1-driven FGFR3 mRNA stabilization occurs through this
mechanism remains to be clarified.
Paxillin antisense RNA 1 (PXN-AS1), a lncRNA overlapping PXN mRNA, was identi-
fied after discovering alternative splicing events on a transcriptome sequencing analysis
of a hepatocellular carcinoma (HCC) cell line with stable deletion of Muscleblind-like-3
(MBNL3), an oncofetal splicing factor. Two main transcripts were identified: lncRNA
PXN-AS1-L (containing exon 4) and lncRNA PXN-AS1-S (lacking exon 4). Both, PXN-
AS1-L and PXN-AS1-S, were preferentially expressed in the cytoplasm, but had different
regulatory effects on the expression of the PXN transcript. While PXN-AS1-L upregulated
PXN protein, PXN-AS1-S downregulated it. Interestingly, PXN-AS1-L upregulated PXN
mRNA by preventing miRNA-24-AGO2 complex binding to the 3′UTR of PXN mRNA [48].
The lncRNA Sirt1 antisense (Sirt1-AS) is transcribed from the Sirt1 antisense strand
and has been shown to interact with Sirt1 mRNA, forming an RNA duplex that increases
stability of its paired transcript, prolonging its half-life up to 10 h and eventually aug-
menting SIRT1 protein expression [49]. Using luciferase assay experiments it was shown
that Sirt1-AS lncRNA interacted with the 3′UTR of the Sirt1 mRNA transcript. This in-
teraction masked miR-3a binding sites, avoiding miR-3a-driven Sirt1 mRNA degradation.
Interestingly, SIRT1 is a NAD-dependent class III protein deacetylase, which regulates
the balance between myoblast proliferation and differentiation, and plays a crucial role in
muscle formation [50]. Thus, lncRNA Sirt1-AS might participate in myogenesis by blocking
miR-34a binding to Sirt1 mRNA which turns in increased SIRT1 protein and increased
myoblast proliferation.
Similar to Sirt1-AS, a lncRNA named Urothelial Cancer Associated 1 (UCA1) has been
shown to regulate mRNA stabilization through directly binding to 3′UTRs of target mRNAs
to protect them from miRNA-mediated degradation [51].
Other mechanisms by which lncRNAs block the effect of miRNAs on mRNA degrada-
tion are the ones described in the “Competing endogenous RNA” hypothesis, in which
lncRNAs compete with miRNAs or RBPs to bind the same common target sequence in
mRNAs. Some examples of lncRNAs that act as ceRNAs are described in the follow-
ing paragraphs.
In addition to the ability to prevent miRNA-induced degradation by binding to
mRNA transcripts, it has been described that UCA1 can also control mRNA stabilization
and gene expression by sponging miRNAs that negatively regulate gene expression [51].
In this specific case, lncRNA UCA1 was implicated in the progression of colorectal cancer
through its capacity to control a ceRNA network that fostered upregulation of several
genes, including ANLN, BIRC5, IPO7, KIF2A, and KIF23.
OIP5 Antisense RNA 1 (OIP5-AS1) is the mammalian homolog of Cyrano gene in
zebrafish and it is important for controlling neurogenesis during development [52]. It is
located upstream of the OIP5 sense gene, but they do not overlap. It is known to act as
a ceRNA for miR-143-3p in cervical cancer (CC) cells, sustaining the expression of miR-
143-3p-targets, ITGA6 [53] and SMAD3 [54], and promoting proliferation, migration and
invasion of CC cells [53,54].
Another lncRNA acting as a ceRNA that affects mRNA stability is MACC1 Antisense
RNA 1 (MACC1-AS1), an intronic antisense lncRNA located between the fourth and fifth
exon of MACC1, a transcriptional regulator of epithelial-mesenchymal transition (EMT) [55]
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that enhances gastric tumor progression [56]. It shares binding sites for miR-384 and miR-
145-3p within PTN and c-Myc transcripts respectively, which are two well-known oncogenic
genes [57]. Similar to lncRNA OIP5-AS1, MACC1-AS1 has the capacity to sequester miR-384
and miR-145-3p, sustaining the stability of PTN and c-Myc mRNAs, and promoting cell
proliferation and tumorigenesis.
Other lncRNA that also acts as a miRNA sponge is lncRNA PTENP1pg1 [58]. PTENpg1
controls the expression of the tumor suppressor gene PTEN, and thus, plays a crucial role
in tumorigenesis processes. Interestingly, antisense to this PTENP1pg1, there is another
lncRNA named PTENP1pg1-AS, which has two isoforms, alpha and beta. While the
alpha isoform functions in trans and epigenetically modulates PTEN transcription by the
recruitment of DNMT3a and EZH2, the beta isoform interacts with PTENpg1 through an
RNA:RNA pairing interaction, affecting PTEN protein output via changes of PTENpg1
stability and microRNA sponge activity.
It is also worth mentioning the lncRNA uc.173 that inhibits miRNA function through
a molecular mechanism that implies posttranscriptional reduction of a pri-miRNA. This
lncRNA is transcribed from an ultraconserved region (UCR) in human chromosome 3.
UCRs represent conserved sequences of the human genome that are likely to be functional
but do not have coding potential [59]. RNA molecules transcribed from UCRs originate
from genomic regions located in both intra- and intergenic regions with almost perfect
evolutionary conservation in most of the mammalian genomes, suggesting that may have a
key function in cell physiology and pathogenic processes [59]. Indeed, lncRNA uc.173 has
been described to be implicated in intestinal mucosal cell growth and renewal [60]. This
lncRNA, which is highly expressed in intestinal mucosa, stimulates intestinal epithelial
cell renewal by downregulating miRNA195 expression through posttranscriptional reduc-
tion of pri-miR-195. Although the precise molecular mechanisms by which this lncRNA
destabilizes the pri-miR-195 transcript are unknown, it seems that the process is achieved
through a direct lncRNA-mRNA interaction that enhances the degradation of pri-miR-195
transcript. Downregulation of miRNA195 by lncRNA uc.173 results in upregulation of
genes implicated in intestinal epithelium growth [60].
Finally, another interesting example is the tumor-promoting lncRNA ncNRFR (non-
coding Nras functional RNA). This lncRNA contains a 22-nucleotide sequence that is identical
to miRNA let-7a and differs from other miRNAs (let-7b, let-7c, let-7d, let-7e, let-7f, let-7g,
let-7i, and miR-98) in only 1–4 nucleotides [61]. Overexpression of ncNRFR in a cell line of
colon epithelial cells increased the activity of a heterologous reporter bearing a miRNA
let-7 target site, suggesting that ncNRFR lowered miRNA let-7 function. The miRNA let-7 is
a tumor suppressor that inhibits the expression of several oncogenes, and thus tumorigenic
function of ncNRFR might be linked to its ability to suppress the action of miRNA let-7
upon endogenous target mRNAs. The molecular mechanisms by which ncNRFR blocks
let-7 remain to be clarified, although taking into account the high homology in the sequence
of these two ncRNAs, it is plausible to think that ncNRFR might directly compete with let-7
to bind target mRNA transcripts and inhibit let-7-mediated mRNA degradation.
In summary, during the last few years it has become apparent that there is a significant
crosstalk between miRNAs and lncRNAs in the regulation of gene expression. Indeed,
various ceRNAs have already been identified and their capacity either to sequester miRNAs
or to block miRNA binding to target mRNAs has been widely described. Sequestration
or blocking of miRNAs by lncRNAs implies a reduced interaction of the miRNAs with
their target mRNAs, which eventually turns into increased mRNA stability and expres-
sion. Although this field of research has just started to emerge, future studies analyzing
the interaction between these two non-coding molecules will explain many of the “un-
knowns” that still linger regarding the regulation of gene expression, both in basal and
pathogenic conditions.
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3. Interaction between lncRNAs and RBPs in mRNA Stabilization
It is well established that AU-rich elements (AREs) [62] and GU-rich elements
(GREs) [63] are distinct sequence elements in the 3′-UTR of mRNAs. These regions are
among the most common determinants of RNA stability in mammalian cells by which
various RNA binding proteins (RBPs), including both stabilizing and destabilizing factors
bind to, thereby modulating mRNA stability and/or translational efficiency [64]. There
exist hundreds of different RBPs with a diverse number of functions through distinct RNA
binding domains to which proteins bind and affect RNA fate [65].
A wide variety of research works have shown how RBPs directly bind to mRNA to
accelerate mRNA decay or affect translation (increasing or blocking the processes) [64,66].
Interestingly, more and more lncRNAs are being described to also bind RBPs [67–69].
One of the best studied lncRNAs, Xist, can form ribonucleoprotein complexes (RNPs) in the
nucleus to affect target gene transcription regulation [70]. It has been shown that lncRNAs
can also be cytoplasmic and bind RBPs to affect other mRNA metabolism processes such
as mRNA stability and turnover [71–73]. Depending on which factors interact with a given
lncRNA, this could increase or decrease the targeted mRNA.
In some cases, lncRNAs bind to mRNA transcripts and help to recruit RBPs (stabilizing
or destabilizing) affecting mRNA levels. For example, the LncRNA-assisted stabilization
of transcripts (LAST) can stabilize CCND1 mRNA through protection against nuclease
activity by promoting the interaction between the RBP named CNBP and the 5′UTR of
CCND1 mRNA [74]. In other cases, lncRNAs prevent RBP and target mRNAs interaction
by binding the mRNA transcript. This is the case of the lncRNA Sros1, which blocks the
binding of Stat1 mRNA to the RBP CAPRIN1, stabilizing the Stat1 mRNA [75], and of
lncRNA 7SL, which interacts with the 3′UTR of TP53 mRNA, thereby preventing HuR
binding and repressing TP53 translation [76].
Another example is PDCD4 Antisense RNA 1 (PDCD4-AS1), a NAT affecting stability
of PDCD4, which is a tumor suppressor coding gene implicated in breast cancer (BC) [77].
In a study by Jadaliha et al. [78], overlapping regions between PDCD4-AS1 and PDCD4
were reported. Thus, PDCD4-AS1 and PDCD4 mRNA were found to form an RNA duplex,
inducing an increase in PDCD4 mRNA stability. In this case, RNA duplex formation
prevented the interaction between PDCD4 mRNA and HuR [79]. Although HuR usually
acts as a stabilizing protein, it has been shown that HuR can form a complex with KSRP
to destabilize mRNA molecules and induce a significant reduction in specific protein
levels [79].
It is also possible that lncRNA-RBPs interactions influence downstream target mRNA.
In turn, LINC00324 [80], TRPM2 Antisense RNA (TRPM2-AS) [81], lncRNA MY [82], lncRNA
MEG3 [83], lncRNA Gadd7 [84], lncRNA FIRRE [85], or lncRNA H19 [86] among others, can
bind different RBPs (both stabilizing and destabilizing), and thus affect target mRNA decay.
There are also lncRNA-RBP interactions that would indirectly affect mRNA. There
are some lncRNAs that modulate RBP activity and hence, will affect downstream mRNA
levels. LncRNA NORAD has been described to sequester PUMILIO proteins, which are key
regulators for many mRNA stability and translation processes. Thus, NORAD-PUMILIO
interaction represses mRNA stability and translation of target mRNAs [87]. LncRNAs
OCC1 and OIP5-AS1 have also been described to bind HuR (a RBP that binds to thousands
of mRNAs). While OCC1 enhances HuR degradation [88], OIP5-AS1 functions as a sponge
for HuR and prevents binding to its targets [89]. In the case of treRNA1, this lncRNA
downregulates the expression of E-cadherin by suppressing the translation of its mRNA.
TreRNA1 forms an RNP complex that, in turn, binds to eIF4G1 (an initiation factor of
protein synthesis) affecting translation of the target mRNA [90].
It is also known that RBPs can influence lncRNA stability, that could also affect lncRNA
function and target mRNAs at different levels. LincRNA-p21 interacts with target CTNNB1
and JUNB mRNAs and inhibits their translation efficiency. However, HuR RBP can inhibit
the expression of lincRNA-p21 by inducing its degradation, which promotes the binding
of HuR to CTNNB1 and JUNB mRNAs enhancing their translation, thus increasing the
Non-coding RNA 2021, 7, 3 7 of 13
levels of these proteins [91]. The cytoplasmic RBP HuD can also increase the stability of
BACE1-AS to further influence target mRNA stability [92].
However, lncRNAs can also reduce mRNA stability, making transcripts prone to
degradation. One mechanism by which this happens is the Staufen 1 mediated decay.
Staufen 1 (STAU1) protein binds the 3′UTR that contain duplex RNA structures to mediate
mRNA decay and regulate gene expression [93]. LncRNAs have been found to form STAU1
binding sites by interacting with the 3′UTR of coding genes, thus downregulating their
expression [94]. TINCR lncRNA was first found to bind STAU1 protein in the context of
epidermal differentiation [95]. Further studies performed in gastric cancer, confirmed the
binding of TINCR to STAU1 protein and found that this interaction induced the STAU1
mediated decay of KLF2 mRNA. KLF2, which induces apoptosis, was described to be
reduced in the cancer tissues, opposite to what happens to TINCR. Thus, interaction of
TINCR lncRNA with STAU1 in cancer cells induces the degradation of KLF2, preventing
apoptosis and contributing to the oncogenic potential of gastric carcinoma [96]. Addition-
ally, other mechanisms of lncRNA-mediated mRNA degradation have also been described.
As it is the case of aHIF antisense lncRNA, which overlaps the 3′UTR of HIF1a coding
gene, and has the ability to destabilize HIF1a mRNA, subsequently decreasing HIF-1α
protein expression in response to chronic hypoxia [97]. Rossignol F. et al. hypothesized
that this destabilization occurs via aHIF-mediated exposure of AU rich elements present in
the 3′ UTR of HIF1a mRNA, although the molecular mechanisms by which the mRNA is
degraded have not been described yet [98].
All these RNA-protein complexes rely mostly in RNA secondary and tertiary struc-
tures that allow the direct interaction between molecules. Therefore, impairment of RNA
structure will affect binding and function of the complex, leading to dysregulation of the
related pathways [65,99]. There is growing evidence about disease-associated SNPs affect-
ing lncRNA structure [100,101]. Taking into account that many complex disease-associated
SNPs are enriched within lncRNAs [102], identifying those lncRNAs and how their binding
to RBPs is affected could help find key targets in the associated diseases. One example is
lnc13, which regulates the stability of STAT1 mRNA in pancreatic beta cells [103]. Lnc13
was first discovered in the context of celiac disease, a chronic inflammatory disorder of the
intestine, where it has a stability-unrelated function and it regulates gene expression in
the chromatin [104]. However, Gonzalez-Moro I. et al. recently related lnc13 with other
autoimmune disorder, type 1 diabetes (T1D), as they found that upregulation of lnc13
in pancreatic beta cells induces the activation of the pro-inflammatory STAT1 pathway
promoting the production of downstream inflammatory chemokines. Lnc13 was found
to enhance STAT1 protein levels by stabilizing its mRNA via interaction with the protein
PCBP2 (Poly(rC)-binding protein 2) in the cytoplasm. Viral infections, which have been
proposed as triggering factors for T1D [105], were found to induce lnc13 translocation from
the nucleus to the cytoplasm, enabling the interaction of STAT1 mRNA with PCBP2, which
promotes the signaling events that will ultimately lead to pancreatic beta cell destruction
and T1D development [103].
Finally, the cell specific expression and functions of lncRNAs should be taken into
consideration as this broadens the pathways that can be affected by lncRNA function.
For example, Linc-RoR interacts with both hnRNP I (stabilizing factor) and AUF1 (destabi-
lizing factor), with an opposite consequence in their interaction with c-Myc mRNA [106].
Alternatively, lncRNA Epr changes Cdkn1a gene expression by affecting both its transcrip-
tion and mRNA decay through its association with the transcription factor SMAD3 or the
RBP KHSRP, respectively. KHSRP is predominantly an mRNA decay promoting factor in
epithelial cells and the interaction with Epr blocks its ability to induce decay of Cdkn1a
mRNA [107,108].
All these mechanisms show the importance of studying lncRNA regulatory roles in
mRNA stability and turnover, but also demonstrate the intricate work beyond studies for
lncRNA functional characterization.
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4. LncRNAs, Epitranscriptomic Changes and mRNA Stability
RNA modifications have been recently involved in the regulation of mRNA stability
and it has been stated that the regulation of mRNA stability through RNA modification is
a crucial step for the tight regulation of gene expression [109]. N6-methyladenosine (m6A)
methylation is the most prevalent RNA modification in mRNAs and noncoding RNAs, and
it has been involved in a wide range of RNA metabolic processes, including stability [110].
YTHDF2, an m6A reader protein, has been described to selectively bind to m6A-
containing mRNAs, resulting in the localization of bound mRNAs from the translat-
able pool to cellular mRNA decay sites, such as processing bodies [110]. In contrast to
the mRNA-decay-promoting function of YTHDF2, insulin-like growth factor 2 mRNA-
binding proteins (IGF2BPs) promote the stability and storage of target mRNAs in an
m6A-dependent manner [111]. The opposite role of IGF2BPs versus YTHDF2 imposes an
additional layer of complexity on m6A function. IGF2BPs and YTHDF2 may recognize
different targets or compete for the same m6A sites to fine-tune expression of shared targets
through controlling the balance between mRNA stabilization and decay [111]. On the
other hand, another m6A reader protein, YTHDF1, actively promotes protein synthesis
by interacting with the translation machinery [112]. Altogether, YTHDF2 and IGF2BPs
control the lifetime of target transcripts, whereas YTHDF1-mediated translation promotion
increases translation efficiency.
In this context, there are few works describing lncRNAs influencing m6A-mediated
mRNA stability. GAS5-AS1 interacts with the tumor suppressor GAS5 and increases its
stability by influencing the interaction between GAS5 mRNA and the RNA demethylase
ALKBH5 leading to a decreased GAS5 m6A methylation. Moreover, it was shown that
m6A-mediated GAS5 mRNA degradation relies on YTHDF2-dependent pathway [113].
LINC00470 associates with PTEN mRNA and suppresses its stability through interaction
with the m6A writer METTL3. In addition, LINC00470-METTL3-mediated PTEN mRNA
degradation also relies on YTHDF2 [114]. Lastly, LIN28B-AS1 is able to regulate mRNA
stability of LIN28B by directly interacting with IGF2BP1 but not with LIN28B, as IGF2BP1
affects LIN28B mRNA stabilization [115].
In the context of mRNA-lncRNA interactions, lncRNA LNC942, upregulated in breast
cancer, has been described to interact with the methylase METTL4 driving it to the mRNA
of target genes CXCR4 and CYP1B1. These two genes are involved in breast cancer initiation
and progression, and their methylation augments the stability of the mRNA molecules,
which results on higher protein levels and induction of tumorigenesis [115] probably due
to an increased interaction with IGF2BP and YTHDF1 readers.
5. Concluding Remarks and Future Prospects
Correct tuning of mRNA stability is a crucial process to maintain appropriate home-
ostasis, and thus its dysregulation may lead to the development of several pathologies,
including cancer. Stability of mRNA molecules is tightly regulated by several mechanisms,
including the action of lncRNA molecules. During the last few years, lncRNAs have been
implicated in the modulation of mRNA stability and several mechanisms of action have
been described. On the one hand, they can prevent miRNA- and RBP-binding to target
mRNAs by blocking target binding sites through direct lncRNA-mRNA interaction. On the
other hand, they can sequester miRNAs and RBPs to avoid their interaction with target
mRNAs, or to inhibit RBP-driven posttranscriptional modifications that affect mRNA
stability. Thus, lncRNAs have emerged as crucial regulators of mRNA stability, another
molecular mechanism by which these non-coding molecules participate in the regulation
of gene expression.
Taking into account that lncRNAs play important roles in the regulation of mRNA
stability, the functional characterization of the molecular mechanisms by which these non-
coding molecules participate on mRNA equilibrium maintenance will open the door to the
development of new lncRNA-based strategies to modify mRNA half-life and subsequent
protein expression. Additionally, the functional understanding of lncRNAs that regulate
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mRNA stability in non-mammalian organisms as Drosophila melanogaster or zebrafish,
which are easier to genetically manipulate, will help find human orthologous lncRNAs
important in mRNA biology. As described formerly in this review, lncRNA-driven mRNA
stability changes might impact several biological processes which are important, in both,
health and disease. Thus, a better understanding of how lncRNAs act on mRNA stability
will provide useful information for the development of new therapeutic strategies to treat
and/or cure several diseases in which a dysregulated gene expression pattern is responsible
of their development.
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